Research Article

Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things

Zuoming Bai, Jianguo Wang, Mingming Kang, Peng Guo, and Dong Wang

Department of Orthopedics, The Second Hospital of Shanxi Medical University, Taiyuan, 030001 Shanxi, China

Correspondence should be addressed to Dong Wang; wanghai@sydey.org.cn

Received 29 June 2022; Revised 5 August 2022; Accepted 8 August 2022; Published 16 August 2022

Academic Editor: Jun Yang

Copyright © 2022 Zuoming Bai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things. Methods. The data of 120 patients admitted to our hospital from January 2019 to December 2020 were retrospectively analyzed. According to the patients’ condition and medication wills, they were divided into the experimental group (n = 68) and the control group (n = 52). All patients were given chronic disease management based on the mobile terminals for the Internet of Things, and they received the treatment of bisphosphonates and calcium, with the supplement of calcium at a daily dose of 1000 mg. The control group was given alendronate sodium once a week, and the experimental group was given pamidronate disodium by intravenous infusion three times a month, with the treatment cycle as 1 year. The patients’ bone mineral density (BMD) values and the pain indexes were compared after treatment.

Results. There was no statistical difference in general information between the two groups (p > 0.05). The BMD values of the lumbar vertebrae L2-L4, total hip, and femur neck at 6 months and 1 year after treatment in the experimental group were significantly higher than those in the control group (p < 0.001). The pain scores at 6 months and 1 year after treatment in the experimental group were significantly lower than those in the control group (p < 0.001). Conclusion. The treatment of pamidronate disodium combined with calcium based on the mobile terminal platform for the Internet of Things can reduce the severity of pain in elderly patients with osteoporosis and improve the BMD, which has a generalization value.

1. Introduction

Osteoporosis is a chronic progressive systemic metabolic osteopathy characterized by a low bone mineral density (BMD). The bone microarchitecture of patients is damaged, and the bone fragility is aggravated. Patients with mild conditions in the early stage have no obvious symptoms, and the diffuse pain or even systemic osteodynia can occur with the progress of disease. The incidence of fractures significantly increases [1, 2], which seriously affects the patients’ quality of life. In recent years, with the aggravation of the population aging in China, the incidence of osteoporosis has increased, and the relevant data predict that the number of patients with osteoporotic fractures will reach 6 million by 2050 in China with the corresponding medical expenditure more than RMB 100 billion [3, 4]. Therefore, the deepening of clinical research on osteoporosis is beneficial for reducing the future medical burden in China and improving the prognosis of elderly patients with osteoporosis. At present, calcium is the main medicine for the treatment of osteoporosis, but the calcium treatment alone cannot exert an ideal prevention and control effect, and elderly patients with low calcium absorption rate in intestinal tract and 1α-hydroxylase activity of kidney cannot benefit from it [5, 6]. In addition to calcium, bisphosphonates are also the first-line drug for the treatment of osteoporosis, which can
inhibit the bone remodeling, increase the BMD, improve the bone microarchitecture of patients, and reduce the possibility of fracture [7]. Since the bisphosphonates are prone to induce the adverse reactions, there are a few studies on the application of bisphosphonates in elderly patients with osteoporosis. Filippo et al. have found that zoledronic acid is the most likely to induce the adverse reactions, followed by pamidronate disodium and alendronate sodium [8]. This study did not compare the medication safety, which was the limitation of this study, but the safety of pamidronate disodium has been confirmed in various diseases. Pamidronate disodium has the same efficacy and the incidence of adverse reactions in alleviating and delaying the occurrence time of skeletal-related events in non-small-cell lung cancer with bone metastasis, and the use of zoledronic acid after ineffective treatment of pamidronate disodium can delay the occurrence time of skeletal-related events in non-small-cell lung cancer with bone metastasis. This retrospective study was conducted in our hospital from January 2019 to December 2020 to explore the efficacy and the incidence of adverse reactions, there are a few studies on the application of bisphosphonates in elderly patients with osteoporosis. Pamidronate disodium, as a new generation of bisphosphonates, can effectively inhibit the activity of osteoclasts, hinder the bone resorption mediated by osteoclasts, repair the osteolytic lesions, and slow down the rate of organismal bone resorption, thus exerting an impact on preventing the osteoporosis [9]. Most importantly, pamidronate disodium is often used in the treatment of bone metastasis of advanced malignant tumors. The medicine can inhibit the synthesis of osteoclasts and the release of nociceptive transmitters such as prostaglandin and reduce the symptoms of osteodynia, which plays an important role in improving the patients’ quality of life. Most elderly patients with chronic diseases have the problem of low medication compliance, and low medication compliance is an important factor affecting the treatment effect of patients. Most literature shows that the compliance of elderly patients gradually decreases after leaving hospital; so, it is crucial to improve the medication compliance of patients. The mobile terminal platform for the Internet of Things can exert a monitoring role through multimode diagnosis and treatment, provide strong external support, and maintain medication compliance in elderly patients with osteoporosis. At present, there is no clinical research on the combined application of disodium pamidronate and calcium in the treatment of elderly osteoporosis. Based on the mobile terminal platform for the Internet of Things, in this study, the supervision and management of medication for elderly patients with osteoporosis were strengthened, and the actual effects of pamidronate disodium combined with calcium in the treatment of elderly osteoporosis were explored. The reports are as follows.

2. Materials and Methods

2.1. Research Design. This retrospective study was conducted in our hospital from January 2019 to December 2020 to explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things. The blind level of this study was double-blind. The study subjects and researchers did not understand the grouping of this experiment, and the research designers were responsible for arranging and controlling the experiment.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria were as follows: (1) patients were diagnosed with primary osteoporosis according to the biochemical examination of bone metabolism in accordance with the diagnostic criteria of osteoporosis recommended by the International Society of Clinical Densitometry (ISCD) [10] and American college of radiology [11]. (2) Patients had the clinical manifestations with spontaneous pain in the whole body, waist, thorax, and back. (3) The BMD in patients measured by dual-energy absorptiometry was lower than 2.5 standard deviations below the mean in healthy people of the same age and sex. (4) Patients had not taken any drugs affecting the bone metabolism in the last three months. (5) The age of patients was more than 70 years old. (6) All patients were treated in our hospital during the whole process with the complete clinical information. (7) Patients were cooperative to complete the follow-up.

Exclusion criteria were as follows: (1) patients with secondary osteoporosis due to the endocrine metabolism, alimentary deficiency, and rheumatism; (2) patients who had taken drugs that might affect the bone metabolism in the last three months; (3) patients with the history of malignant tumor and cardiovascular disease or patients with the diseases that could affect the bone metabolism; (4) patients with the irrational drug use that might have the undefined treatment effects; (5) patients with the incomplete clinical information; (6) patients without complete follow-up; and (7) patients with psychiatric disorders and who could not communicate with others.

2.3. Procedures. In this study, 120 patients were divided into the experimental group (n = 68) and the control group (n = 52) according to the patients’ condition and medication wills. All patients were given the chronic disease management based on the mobile terminals for the Internet of Things, and they received the treatment of bisphosphonates and calcium. On the day when the patients agreed to participate in the study, the study group collected the data of socio-demography and clinical manifestations. After the patients began to receive the treatment, they were given the follow-up for 1 year to investigate the changes of BMD and the pain perception.

2.4. Moral Consideration. This study was in line with the principles of Declaration of Helsinki (2013) [12], and patients signed the informed consent.

2.5. Standards of Withdrawing from Experiment. In the following conditions, the study group judged that patients were inappropriate for continuing the experiment, and the case record forms of patients were retained, but the data analysis was not performed: (1) patients with exacerbation during the experiment, (2) patients with severe comorbidities or complications, and (3) patients who requested the withdrawal from the clinical trials.

2.6. Methods. All patients were given the chronic disease management based on the mobile terminals for the Internet of Things, and the project of healthcare cloud was constructed. The integrated management system of osteoporosis
was consolidated into the cloud platform to build a remote monitoring platform for osteoporosis medication. Patients needed to register and report on the mobile terminal platform, and they were supervised and managed through the mobile terminal platform for the Internet of Things.

Control group was as follows: the control group was given the alendronate sodium (Beijing Wansheng Pharmaceutical Co., Ltd.; NMPA approval No. H20058996) once a week at a single dose of 70 mg with 300 ml of warm water on an empty stomach in the morning. Patients should keep standing or sitting within half an hour after taking the medicine and then take food. In addition, patients were given calcium (Shenzhen Haiwang Pharmaceutical Co., Ltd.; NMPA approval No. H10950029) at a daily dose of 600 mg and 2 pellets of active vitamin D (Sinopharm Xingsha Pharmaceutical Co., Ltd.; NMPA approval No. H20173093).

The experimental group was as follows: The supplement of calcium and vitamin D in the experimental group was the same as those in the control group. In addition, the pamidronate disodium (Shenzhen Haiwang Pharmaceutical Co., Ltd.; NMPA approval No. H19980130) at a single dose of 30 mg diluted in 250 ml of 5% glucose once a day on 3 consecutive days was given by intravenous infusion three times a month.

2.7. Standards of Observation

(1) General information: the general information of patients such as gender, age, body mass, BMI, the course of disease, the severity of osteoporosis, education level, income level, payment of medical expenses, and the place of residence in the two groups were recorded

(2) BMD: the BMD values of patients were detected before treatment and at 6 months and 1 year after treatment using a dual energy X-ray absorptiometry (DTX-200; NMPA (I) 20113302208) by Osteometer MediTech, USA. Before the examination, the precision of instruments was calibrated by the model of lumbar vertebrae with the coefficient of variation (CV) as 0.40%. After the patients kept lying flat, the bone scan of lumbar vertebrae (L2-4) in supine position was performed, and the hip was scanned in knee flexion position of both lower extremities. The BMD values of lumbar vertebrae, total hip, and femur neck were recorded

(3) Pain indexes: before treatment, and at 6 months and 1 year after treatment, the patients’ severity of pain was evaluated with an 11-point numeric rating scale (NRS). In the scale, the number of 0-10 on the straight line represented the severity of pain, and the patients chose the spot which was consistent with the severity of pain according to their own condition after visual estimation. 0 point represented the painlessness, 1-3 points represented the mild pain that did not interfere with sleep, 4-6 points represented the moderate pain, 7-9 points represented the severe pain that could not fall asleep or woke up from the pain during sleep, and 10 points represented the baryodynia

2.8. Statistical Treatment. In this study, the experimental data were processed by SPSS 20.0, and GraphPad Prism 7 (GraphPad software, San Diego, USA) was used to draw pictures of the data. The enumeration data and measurement data were tested by $x^2$ and t-test. When $p < 0.05$, the differences were considered to be statistically significant.

3. Results

3.1. Comparison of Patients’ General Information. There was no significant difference in the general information between the two groups, see details in Table 1.

3.2. Comparison of Patients’ BMD Values. The BMD values of the lumbar vertebrae L2-4, total hip, and femur neck at 6 months and 1 year after treatment in the experimental group were significantly higher than those in the control group ($p < 0.001$), see details in Figure 1.

3.3. Comparison of Patients’ Pain Indexes. There was no statistical difference in the pain scores between the experimental group and the control group before treatment ($7.65 \pm 0.64$ vs. $7.65 \pm 0.55$, $p > 0.05$). The pain scores at 6 months and 1 year after treatment in the experimental group were significantly lower than those in the control group ($4.24 \pm 0.55$ vs. $5.67 \pm 0.61$, $3.01 \pm 0.44$ vs. $4.13 \pm 0.62$, $p < 0.001$).

4. Discussion

Due to the existence of degenerative deformation during the senescence of the body, the calcium absorption rate in gastrointestinal tract and the sex hormone levels will decrease with age [13], so that age is a risk factor for osteoporosis, and higher age is associated with a higher incidence of osteoporosis [14]. Epidemiological data have shown that the number of elderly patients with osteoporosis is close to 100 million ranking third in chronic diseases among residents, and the incidence of osteoporotic fractures is as high as 7.5% in China. The rate of hip fracture in elderly patients increased by three times during 2012-2016, and the mortality of patients within one year is as high as 20.0%. In addition, this number will continue to rise further with the aggravation of the population aging in China [15-17]. Early measures of prevention and treatment can effectively improve the quality of life in elderly patients with osteoporosis and reduce the medical burden in China. At present, the calcium treatment is the basic treatment for senile osteoporosis. Calcium, as a key component of bone, plays an important role in reducing the osteoporosis. Some studies have shown that calcium can prevent the age-related calcium deficiency, thereby exerting the effect on prevention and treatment of senile osteoporosis [18]. However, the effect of calcium alone is limited, and it is necessary to cooperate with other therapeutic agents. At present, the common therapeutic agents used for osteoporosis also include bisphosphonates, calcium, and sex hormone supplementation. Bisphosphonates can maintain
the effect on antiosteoporotic fracture for several years even after discontinuation, while the antifracture efficacy of other drugs decreases, indicating that bisphosphonates have a favorable value in long-term antiosteoporosis [19].

Scholars Tim et al. have found that the treatment with bisphosphonates for 4 years can reduce the risk of hip fracture by 50.0%. The annual growth rate of BMD value is 1.0% at a daily dose of 150 mg, and the densities of lumbar vertebrae and hip can increase continuously [20]. The results of this study showed that the densities of lumbar vertebrae, total hip, and femur neck in the two groups were increased after the treatment of bisphosphonates and calcium. However, the BMD values of lumbar vertebrae L2-L4, total hip, and femur neck in the experimental group at 6 months and 1 year after treatment were significantly higher than those in the control group (p < 0.001), suggesting that the intensity of pamidronate disodium by intravenous injection was higher than that of alendronate sodium by oral administration. Pamidronate disodium can fully adhere to the surface of trabecular bone by intravenous injection, which can directly inhibit the phagocytic factors of osteoclasts, hinder the effects of osteoclasts on dissolution and destruction of bone, and slow down the bone absorption, thereby preventing the bone dissolution [21]. Baroncelli et al. have believed that pamidronate disodium can promote the bone formation in patients with spontaneous juvenile osteoporosis, improve the BMD, reduce the incidence of fractures, and prevent the disability after fractures [22]. In addition, pamidronate disodium has the analgesic effect, especially in relieving the symptoms of bone pain. It can inhibit the premature maturation of osteoclasts, slow down the release frequencies of nociceptive transmitters such as prostaglandins and lactic acid and inflammatory transmitters, and relieve the osteolytic pain [23]. At present, pamidronate disodium is often used for analgesia in bone metastasis of malignant tumor. Some scholars have believed that the analgesic effect of this drug in osteoporosis is better than that in bone metastasis of malignant tumor [24]. This study showed that the pain scores at 6 months and 1 year after treatment in the experimental group were significantly lower than those in the control group (p < 0.001), indicating that pamidronate disodium has a definite analgesic effect in elderly patients with osteoporosis, which can effectively reduce the patients’ severity of pain and has a great significance for improving the quality of life.

It is worth noting that the elderly patients with chronic diseases have the characteristic of poor medical compliance behavior [25], and patients with osteoporosis need long-term medication. In clinic, it is generally agreed that the treatment time of osteoporosis should be more than 1 year. Therefore, no matter what kind of drugs are used, attention should be paid to maintain the medication compliance of

| Groups                  | Experimental group (n = 68) | Control group (n = 52) | X²/t   | p    |
|-------------------------|-----------------------------|------------------------|--------|------|
| Gender                  |                             |                        |        |      |
| Male                    | 34                          | 28                     | 0.175  | 0.676|
| Female                  | 34                          | 24                     |        |      |
| Age (years)             | 73.99 ± 3.16                | 74.44 ± 3.65           | 0.723  | 0.471|
| Body mass (kg)          | 62.65 ± 2.65                | 62.74 ± 2.40           | 0.192  | 0.848|
| BMI (kg/m²)             | 22.11 ± 1.20                | 22.13 ± 1.24           | 0.089  | 0.929|
| Course of disease (years)| 5.29 ± 1.94                | 4.98 ± 1.66            | 0.922  | 0.358|
| Severity degree         |                             |                        | 0.369  | 0.544|
| Moderate grade          | 48                          | 34                     |        |      |
| Severe grade            | 20                          | 18                     |        |      |
| Education level         |                             |                        |        |      |
| Primary school          | 30                          | 26                     | 0.410  | 0.522|
| Senior high school      | 28                          | 20                     | 0.091  | 0.764|
| University and above    | 10                          | 6                      | 0.256  | 0.613|
| Income level (yuan)     |                             |                        | 0.019  | 0.890|
| ≥4000                   | 41                          | 32                     |        |      |
| <4000                   | 27                          | 20                     |        |      |
| Payment of medical expenses |                        |                        |        |      |
| Medical insurance       | 30                          | 22                     | 0.039  | 0.843|
| Commercial insurance    | 24                          | 18                     | 0.006  | 0.938|
| Others                  | 14                          | 12                     | 0.108  | 0.743|
| Place of residence      |                             |                        | 0.016  | 0.901|
| Town                    | 40                          | 30                     |        |      |
| Countryside             | 28                          | 22                     |        |      |
Figure 1: Comparison of patients' BMD values (\( \bar{x} \pm s, \text{g/cm}^2 \)). Notes were as follows: Figure 1(a) shows the BMD value of L2. Figure 1(b) shows the BMD value of L3. Figure 1(c) shows the BMD value of L4. Figure 1(d) shows the BMD value of total hip. Figure 1(e) shows the BMD value of femur neck. There was no statistical difference in the BMD values of lumbar vertebrae L2-4, total hip, and femur neck between the experimental group and the control group before treatment (0.74 ± 0.05 vs. 0.75 ± 0.04, 0.83 ± 0.04 vs. 0.84 ± 0.06, 0.69 ± 0.04 vs. 0.71 ± 0.03, 0.75 ± 0.03 vs. 0.71 ± 0.02, 0.70 ± 0.03 vs. 0.63 ± 0.04, \( p > 0.05 \)). The BMD values of lumbar vertebrae L2-4, total hip, and femur neck in the experimental group at 6 months after treatment were significantly higher than those in the control group (0.84 ± 0.03 vs. 0.77 ± 0.04, 0.83 ± 0.04 vs. 0.78 ± 0.03, 0.90 ± 0.04 vs. 0.84 ± 0.06, 0.69 ± 0.04 vs. 0.71 ± 0.03, 0.65 ± 0.04, 0.70 ± 0.03 vs. 0.63 ± 0.04, \( p < 0.001 \)).
patients to ensure that drugs can play the best effect. Based on the mobile terminal platform for the Internet of Things, this study established a remote monitoring platform for elderly patients with osteoporosis and realized the continuous management of elderly patients, so that the medication effects of the two groups were better. With the development of aging society, the importance of information construction in elderly chronic diseases is increasingly prominent. It is beneficial for elderly patients with osteoporosis to accelerate the construction of the mobile terminal platform for the Internet of Things, and elderly patients with chronic diseases also benefit more.

In conclusion, the treatment of pamidronate disodium combined with calcium based on the mobile terminal platform for the Internet of Things can reduce the severity of pain in elderly patients with osteoporosis and improve the BMD, which has a generalization value.

**Data Availability**

Data to support the findings of this study is available on reasonable request from the corresponding author.

**Conflicts of Interest**

The authors do not have conflicts of interest to declare.

**References**

[1] H. Zhang, A. Wang, G. Shen et al., "Hepcidin-induced reduction in iron content and PGC-1α expression negatively regulates osteoclast differentiation to play a protective role in postmenopausal osteoporosis," *Aging*, vol. 13, no. 8, pp. 11296–11314, 2021.

[2] K. Ebina, M. Hirao, H. Tsuboi et al., "Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis," *Bone*, vol. 140, article 115574, 2020.

[3] Z. Fan, X. Li, X. Zhang, Y. Yang, Q. Fei, and A. Guo, "Comparison of OSTA, FRAX and BMI for predicting postmenopausal osteoporosis in a Han population in Beijing: a cross sectional study," *Clinical Interventions in Aging*, vol. 15, pp. 1171–1180, 2020.

[4] Y. R. Yang, C. W. Li, J. H. Wang et al., "Ubiquitylomes analysis of the whole blood in postmenopausal osteoporosis patients and healthy postmenopausal women," *Orthopaedic Surgery*, vol. 11, no. 6, pp. 1187–1200, 2019.

[5] Y. He, D. Chen, Q. Guo, P. Shi, C. You, and Y. Feng, "MicroRNA-151a-3p functions in the regulation of osteoclast differentiation: significance to postmenopausal osteoporosis," *Clinical Interventions in Aging*, vol. 16, pp. 1357–1366, 2021.

[6] K. Tomonori, M. Akiko, S. Makoto et al., "Denosumab versus romosozumab for postmenopausal osteoporosis treatment," *Scientific Reports*, vol. 11, no. 1, p. 11801, 2021.

[7] G. Yan, Y. Huang, H. Cao, J. Wu, N. Jiang, and X. Cao, "Association of breastfeeding and postmenopausal osteoporosis in Chinese women: a community-based retrospective study," *BMC Womens Health*, vol. 19, no. 1, p. 110, 2019.

[8] F. Migliorini, N. Maffulli, F. Spiezia, G. M. Peretti, M. Tingart, and R. Giorgino, "Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review," *Journal of Orthopaedic Surgery and Research*, vol. 16, no. 1, p. 351, 2021.

[9] C. Lin, S. Yu, R. Jin et al., "Circulating miR-338 cluster activity on osteoblast differentiation: potential diagnostic and therapeutic targets for postmenopausal osteoporosis," *Theranostics*, vol. 9, no. 13, pp. 3780–3797, 2019.

[10] V. Testini, M. T. Paparella, I. Gangai, and G. Guglielmi, "Postmenopausal osteoporosis: current status of bone densitometry," *Obstetrics and Gynecology*, vol. 73, no. 6, pp. 730–743, 2021.

[11] B. G. A. Stuckey, L. A. Mahoney, S. Dragovic, and S. J. Brown, "Celiac disease and bone health: is there a gap in the management of postmenopausal osteoporosis?," *Climacteric*, vol. 23, no. 6, pp. 559–565, 2020.

[12] World Medical Association, "World medical association declaration of Helsinki: ethical principles for medical research involving human subjects," *Journal of the American Medical Association*, vol. 310, no. 20, pp. 2191–2194, 2013.

[13] J. Xiaona, Z. Baozhen, and Z. Dangfeng, "Replication study confirms the association of the common rs1800629 variant of theTNFaGene with postmenopausal osteoporosis susceptibility in the Han Chinese population," *Genetic Testing and Molecular Biomarkers*, vol. 22, no. 4, pp. 246–251, 2018.

[14] Y. Kataoka, Y. Luo, A. Chaimani et al., "Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: a meta-epidemiological study," *Archives of Osteoporosis*, vol. 15, no. 1, p. 21, 2020.

[15] X. Cai, X. Yi, Y. Zhang, D. Zhang, L. Zhi, and H. Liu, "Genetic susceptibility of postmenopausal osteoporosis on sulfide quinine reductase-like gene," *Osteoporosis International*, vol. 29, no. 9, pp. 2041–2047, 2018.

[16] B. Johnson, E. C. Lai, H. T. Ou, H. Li, and B. Stollenwerk, "Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan," *Archives of Osteoporosis*, vol. 16, no. 1, p. 155, 2021.

[17] A. Wawrzy niak, M. Skrzyczak-Zielinska, I. Krela-Kazmierek et al., "Analysis of the tumor necrosis factor superfamily member 11 gene polymorphism with bone mineral density and bone fracture frequency in patients with postmenopausal osteoporosis," *Advances in Medical Sciences*, vol. 65, no. 2, pp. 291–297, 2020.

[18] S. Shetty, B. John, S. Mohan, and T. V. Paul, "Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis," *Archives of Osteoporosis*, vol. 15, no. 1, p. 25, 2020.

[19] The North American Menopause Society (NAMS) and Management of osteoporosis in postmenopausal women. the, "Management of osteoporosis in postmenopausal women: the 2021 Position statement of the North American Menopause Society," *Menopause*, vol. 28, no. 9, pp. 973–997, 2021.

[20] T. Rolvien, P. Milovanovic, F. N. Schmidt et al., "Long-term immobilization in elderly females causes a specific pattern of cortical bone and osteocyte deterioration different from postmenopausal osteoporosis," *Journal of Bone and Mineral Research*, vol. 35, no. 7, pp. 1343–1351, 2020.

[21] P. Sawicki, M. Talalaj, K. Życińska, W. S. Zgliczyński, and W. Wierzb, "Comparison of the characteristics of back pain in women with postmenopausal osteoporosis with and without vertebral compression fracture: a retrospective study at a single osteoporosis center in Poland," *Medical Science Monitor*, vol. 27, article e929853, 2021.
[22] G. I. Baroncelli, F. Vierucci, S. Bertelloni, P. Erba, E. Zampollo, and M. R. Giuca, “Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients,” *Journal of Bone and Mineral Metabolism*, vol. 31, no. 5, pp. 533–543, 2013.

[23] N. Saleh, N. A. Nassef, M. K. Shawky, M. I. Elshishiny, and H. A. Saleh, “Novel approach for pathogenesis of osteoporosis in ovariectomized rats as a model of postmenopausal osteoporosis,” *Experimental Gerontology*, vol. 137, article 110935, 2020.

[24] D. Aghamohammadi, N. Dolatkhah, S. K. Shakouri, P. Hermann, and F. Eslamian, “Ginger (Zingiber officinale) and turmeric (Curcuma longa L.) supplementation effects on quality of life, body composition, bone mineral density and osteoporosis related biomarkers and micro-RNAs in women with postmenopausal osteoporosis: a study protocol for a randomized controlled clinical trial,” *Journal of Complementary and Integrative Medicine*, vol. 18, no. 1, pp. 131–137, 2020.

[25] W. Zhou, Y. Liu, X. Guo, H. Yang, Y. Xu, and D. Geng, “Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis,” *Osteoporosis International*, vol. 30, no. 8, pp. 1581–1589, 2019.